Potential Effects Immunomodulators on Probiotics in COVID-19 Preventing Infection in the Future. A Narrative Review
After the outbreak in December 2019, Coronavirus Disease (COVID-19) has become a global health problem because of its rapid spread throughout the world. To date, there are no effective therapies to treat or prevent COVID-19 infection. Probiotic bacteria are widely used to prevent gastrointestinal infections by modulating intestinal microbiota. Therefore, this literature review focuses on the potential possessed by probiotic bacteria for the prevention of future COVID-19 infections. Information was extracted from PubMed and Google Scholar using the keywords: "COVID-19", "immunomodulator", "inflammation", and "probiotic" and synthesize in a narrative review. The results showed that probiotic bacteria have immunomodulatory activity that can increase immunity against pathogens by regulating the immune system through modulation of intestinal microbiota and interactions with the lymphatic system in the digestive tract. The ability of the immune system regulation by probiotic bacteria has the effect of increasing the body's defense mechanisms against pathogens that infect the respiratory tract. However, further evidence is still needed regarding the effect of probiotic immunomodulators in combating future COVID-19 infections.
Lai, C. C., Shih, T. P., Ko, W. C., Tang, H. J. & Hsueh, P. R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int. J. Antimicrob. Agents 55, 105924 (2020).
Guo, Y.-R. et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Mil. Med. Res. 7, 1–10 (2020).
Sun, P., Lu, X., Xu, C., Sun, W. & Pan, B. Understanding of COVID-19 based on current evidence. J. Med. Virol. 0–1 (2020). doi:10.1002/jmv.25722
Malemud, C. J. Immunomodulators in Autoimmunity and Viral Infections. J. Clin. Cell. Immunol. 09, (2018).
Kanauchi, O., Andoh, A., AbuBakar, S. & Yamamoto, N. Probiotics and Paraprobiotics in Viral Infection: Clinical Application and Effects on the Innate and Acquired Immune Systems. Curr. Pharm. Des. 24, 710–717 (2018).
Prompetchara, E., Ketloy, C. & Palaga, T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pacific J. allergy Immunol. (2020). doi:10.12932/AP-200220-0772
Qin, C. et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China Chuan. Clin. Infect. Dis. (2020). doi:10.1017/CBO9781107415324.004
Mahallawi, W. H., Khabour, O. F., Zhang, Q., Makhdoum, H. M. & Suliman, B. A. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. Cytokine 104, 8–13 (2018).
Raoult, D., Zumla, A., Locatelli, F., Ippolito, G. & Kroemer, G. Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses. Cell Stress 4, 66–75 (2020).
Lehtoranta, L., Pitkäranta, A. & Korpela, R. Probiotics in respiratory virus infections. Eur. J. Clin. Microbiol. Infect. Dis. 33, 1289–1302 (2014).
Mohanty, D. & Ray, P. Evaluation of probiotic and antimicrobial properties of lactobacillus strains isolated from dairy products. Int. J. Pharm. Pharm. Sci. 8, 230–234 (2016).
Monteagudo-Mera, A., Rastall, R. A., Gibson, G. R., Charalampopoulos, D. & Chatzifragkou, A. Adhesion mechanisms mediated by probiotics and prebiotics and their potential impact on human health. Appl. Microbiol. Biotechnol. 103, 6463–6472 (2019).
Garcia-Gonzalez, N., Prete, R., Battista, N. & Corsetti, A. Adhesion properties of food-associated lactobacillus plantarum strains on human intestinal. Front. Microbiol. 9, 1–11 (2018).
Hemarajata, P. & Versalovic, J. Effects of probiotics on gut microbiota: Mechanisms of intestinal immunomodulation and neuromodulation. Therap. Adv. Gastroenterol. 6, 39–51 (2013).
Zhang, C. xing, Wang, H. yu & Chen, T. xin. Interactions between Intestinal Microflora/Probiotics and the Immune System. Biomed Res. Int. 2019, (2019).
McFarland, L. V. Systematic review and meta-analysis of saccharomyces boulardii in adult patients. World J. Gastroenterol. 16, 2202–2222 (2010).
Arora, T., Singh, S. & Sharma, R. K. Probiotics: Interaction with gut microbiome and antiobesity potential. Nutrition 29, 591–596 (2013).
Bellikci-Koyu, E. et al. Effects of regular kefir consumption on gut microbiota in patients with metabolic syndrome: A parallel-group, randomized, controlled study. Nutrients 11, 1–23 (2019).
Lazarenko, L. M. et al. IMUNOBIOTICS ARE THE NOVEL BIOTECH DRUGS WITH ANTIBACTERIAL AND IMMUNOMODULATORY PROPERTIES. ікробіологічний журнал 7, 66–75 (2017).
Villena, J. et al. Immunobiotic Lactobacillus rhamnosus strains differentially modulate antiviral immune response in porcine intestinal epithelial and antigen presenting cells. BMC Microbiol. 14, 1–14 (2014).
Tada, A. et al. Immunobiotic Lactobacillus strains reduce small intestinal injury induced by intraepithelial lymphocytes after Toll-like receptor 3 activation. Inflamm. Res. 65, 771–783 (2016).
Zhang, H. et al. Prospective study of probiotic supplementation results in immune stimulation and improvement of upper respiratory infection rate. Synth. Syst. Biotechnol. 3, 113–120 (2018).
Dickson, R. P., Erb-Downward, J. R. & Huffnagle, G. B. The role of the bacterial microbiome in lung disease. Expert Rev. Respir. Med. 7, 245–257 (2013).
Rosa, D. D. et al. Milk kefir: Nutritional, microbiological and health benefits. Nutr. Res. Rev. 30, 82–96 (2017).
Oeser, K., Maxeiner, J., Symowski, C., Stassen, M. & Voehringer, D. T cells are the critical source of IL-4/IL-13 in a mouse model of allergic asthma. Allergy Eur. J. Allergy Clin. Immunol. 70, 1440–1449 (2015).
Li, B., Zheng, J., Zhang, X. & Hong, S. Probiotic Lactobacillus casei Shirota improves efficacy of amoxicillin-sulbactam against childhood fast breathing pneumonia in a randomized placebo-controlled double blind clinical study. J. Clin. Biochem. Nutr. 63, 233–237 (2018).
Natarajan, N. & Pluznick, J. L. From microbe to man: The role of microbial short chain fatty acid metabolites in host cell biology. Am. J. Physiol. - Cell Physiol. 307, C979–C985 (2014).
Shukla, S. D., Budden, K. F., Neal, R. & Hansbro, P. M. Microbiome effects on immunity, health and disease in the lung. Clin. Transl. Immunol. 6, e133-12 (2017).
He, Y. et al. Gut–lung axis: The microbial contributions and clinical implications. Crit. Rev. Microbiol. 43, 81–95 (2017).
Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020).
Tisoncik, J. R. et al. Into the Eye of the Cytokine Storm. Microbiol. Mol. Biol. Rev. 76, 16–32 (2012).
Raphael, I., Nalawade, S., Eagar, T. N. & Forsthuber, T. G. T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine 74, 5–17 (2015).
Qian, L. J. et al. Early-life gut microbial colonization shapes Th1/Th2 balance in asthma model in BALB/c mice. BMC Microbiol. 17, 1–8 (2017).
Grayson, M. H. et al. Intestinal microbiota disruption reduces regulatory T cells and increases respiratory viral infection mortality through increased IFNγ production. Front. Immunol. 9, 7–9 (2018).
Mortaz, E. et al. Probiotics in the management of lung diseases. Mediators Inflamm. 2013, (2013).
Vareille-Delarbre, M. et al. Immunomodulatory effects of lactobacillus plantarum on inflammatory response induced by klebsiella pneumoniae. Infect. Immun. 87, (2019).
Wu, C. T., Chen, P. J., Lee, Y. T., Ko, J. L. & Lue, K. H. Effects of immunomodulatory supplementation with Lactobacillus rhamnosus on airway inflammation in a mouse asthma model. J. Microbiol. Immunol. Infect. 49, 625–635 (2016).
Kuo, C. et al. Rhinovirus infection induces expression of airway remodelling factors in vitro and in vivo. Respirology 16, 367–377 (2011).
Azad, M. A. K., Sarker, M. & Wan, D. Immunomodulatory Effects of Probiotics on Cytokine Profiles. Biomed Res. Int. 2018, (2018).
Copyright (c) 2020 Muhammad Luthfi Adnan, Miranti D. Dewi
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- The Author retains copyright in the Work, where the term “Work” shall include all digital objects that may result in subsequent electronic publication or distribution.
- Upon acceptance of the Work, the author shall grant to the Publisher the right of first publication of the Work.
- The Author shall grant to the Publisher and its agents the nonexclusive perpetual right and license to publish, archive, and make accessible the Work in whole or in part in all forms of media now or hereafter known under a Creative Commons Attribution 4.0 International License or its equivalent, which, for the avoidance of doubt, allows others to copy, distribute, and transmit the Work under the following conditions:
- Attribution—other users must attribute the Work in the manner specified by the author as indicated on the journal Web site; with the understanding that the above condition can be waived with permission from the Author and that where the Work or any of its elements is in the public domain under applicable law, that status is in no way affected by the license.
- The Author is able to enter into separate, additional contractual arrangements for the nonexclusive distribution of the journal's published version of the Work (e.g., post it to an institutional repository or publish it in a book), as long as there is provided in the document an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post online a prepublication manuscript (but not the Publisher’s final formatted PDF version of the Work) in institutional repositories or on their Websites prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. Any such posting made before acceptance and publication of the Work shall be updated upon publication to include a reference to the Publisher-assigned DOI (Digital Object Identifier) and a link to the online abstract for the final published Work in the Journal.
- Upon Publisher’s request, the Author agrees to furnish promptly to Publisher, at the Author’s own expense, written evidence of the permissions, licenses, and consents for use of third-party material included within the Work, except as determined by Publisher to be covered by the principles of Fair Use.
- The Author represents and warrants that:
- the Work is the Author’s original work;
- the Author has not transferred, and will not transfer, exclusive rights in the Work to any third party;
- the Work is not pending review or under consideration by another publisher;
- the Work has not previously been published;
- the Work contains no misrepresentation or infringement of the Work or property of other authors or third parties; and
- the Work contains no libel, invasion of privacy, or other unlawful matter.
- The Author agrees to indemnify and hold Publisher harmless from the Author’s breach of the representations and warranties contained in Paragraph 6 above, as well as any claim or proceeding relating to Publisher’s use and publication of any content contained in the Work, including third-party content.
Enforcement of copyright
The IJMS takes the protection of copyright very seriously.
If the IJMS discovers that you have used its copyright materials in contravention of the license above, the IJMS may bring legal proceedings against you seeking reparation and an injunction to stop you using those materials. You could also be ordered to pay legal costs.
If you become aware of any use of the IJMS' copyright materials that contravenes or may contravene the license above, please report this by email to email@example.com
If you become aware of any material on the website that you believe infringes your or any other person's copyright, please report this by email to firstname.lastname@example.org